BioSpace News Archive

Tyber Medical LLC, the global leader in private-label medical devices for major orthopedic trauma, extremity and spine companies, has been granted a 510(k) clearance by the U.S. Food and Drug Administration to expand its anatomical plate portfolio and an additional clearance for MR Conditional labeling.

ALX Oncology Holdings Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided clinical development and operational highlights.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results.

Kamada Ltd. today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2022 and provided a business update.

VBL Therapeutics announced that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex-developed, immunoprotective device with the potential to treat type 1 diabetes (T1D).

PerkinElmer Inc. today announced that the Company will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. ET.

Cell One Partners Inc. today announced a strategic partnership to accelerate the development and commercialization of cell and gene therapies.

Ajax Therapeutics, Inc. today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.